Apr 4 |
Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management
|
Apr 2 |
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Apr 2 |
Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
|
Mar 28 |
FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
|
Mar 28 |
Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
|
Mar 28 |
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
|
Mar 28 |
Akebia stock jumps as FDA clears renal anemia therapy
|
Mar 28 |
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
|
Mar 26 |
Akebia Awaits FDA Word On Second Crack At Vadadustat
|
Mar 17 |
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33
|